Clinical Practice Guideline: Immunotherapy for Inhalant Allergy

Area of Science:

• Allergy and Immunology
• Clinical Practice Guidelines
• Immunotherapy

Background:

• Allergen immunotherapy (AIT) is a widely used treatment for allergic rhinitis (AR) and allergic asthma (AA).
• Subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) are common delivery methods.
• Variability exists in AIT initiation and delivery, necessitating evidence-based recommendations for optimal patient care.

Purpose of the Study:

• To identify quality improvement opportunities in inhaled allergen immunotherapy (AIT).
• To provide clinicians with evidence-based recommendations for managing inhaled allergies with AIT.
• To optimize patient care, promote safety and efficacy, reduce care variations, and minimize harm.

Main Methods:

• Development of a clinical practice guideline (CPG) by a guideline development group (GDG).
• Focus on evidence-based quality improvement opportunities.
• Recommendations based on clinical assessment, allergy testing, and patient factors.

Main Results:

• Strong recommendation for clinicians to diagnose and manage anaphylaxis during AIT.
• Recommendations for offering AIT for inadequately controlled AR/AA, patient education on SCIT/SLIT, and appropriate allergen selection.
• Guidance on managing local reactions, duration of treatment, and contraindications for initiating AIT.

Conclusions:

• Clinicians should offer AIT to eligible patients with AR/AA.
• Patient education and careful assessment for contraindications are crucial for safe and effective AIT.
• A minimum treatment duration of 3 years is recommended for symptomatic control.